- Home
- Companies
- kyrgyzstan
- solid tumor
Show results for
Refine by
Solid Tumor Suppliers Serving Kyrgyzstan
56 companies found
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
based inMilan, ITALY
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
Whole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs ...
based inEching,, GERMANY
BIOZOL - World of Science distribution service. We provide you more than 25 Million products of more than 260 partner companies around the world. For our customers we overcome national borders, customs and import regulations. So, you receive for ...
contains DAPI nuclear staining dye, fluorescence mounting medium, no background autofluorescence, slowly hardening over weeks, strong reduction of photobleaching, viscous fluid, water-based ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC ...
based inGoettingen, GERMANY
We provide the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Cancer is the leading cause of death in Japan, with approximately 90% of those deaths said to be caused by solid ...
based inSaint Louis, MISSOURI (USA)
Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...
Sequoia is developing an anticancer compound (SQ1274) for use against solid tumors including ovarian and lung ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
Visualize the Landscape of Tissue-Specific Immunity. Tracking T cells in the tissue where they exert their function can advance our understanding of T-cell immunity. MHC I Dextramer® for in-situ staining reagents can detect spatial distribution, ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics’ latest proprietary ACTengine® manufacturing processes are designed to generate cell product candidates within a short manufacturing window and deliver highly proliferative T cells, with the capability to infiltrate the ...